Skip to content

JASCO JASCO

  • News
  • Events
  • E-Store
  • My Account
  • Contact Us
  • Worldwide
Search
Click to view menu
MENUMENU
  • Products
    • Chromatography
      • HPLC
      • RHPLC
      • UHPLC
      • LC-MS
      • Preparative LC
      • Analytical SFC
      • Semi-Preparative SFC
      • Hybrid SFC
      • Fuel Analysis by SFC-FID
      • Preparative SFC
      • Supercritical Fluid Extraction
      • Chromatography Software
    • Molecular Spectroscopy
      • Circular Dichroism
      • High-Throughput CD
      • Vibrational CD
      • Circularly Polarized Luminescence (CPL)
      • Polarimeters
      • FTIR Spectrometers
      • FTIR Microscopy
      • FTIR Portable
      • Raman Microscopy
      • Palmtop Raman Spectrometer
      • Probe Raman
      • UV-Visible/NIR Spectrophotometers
      • UV-Visible/NIR Microscopy
      • Fluorescence Spectrophotometers
      • Film Thickness
      • Spectra Manager™ Suite
    • Refurbished
      • Refurbished HPLC Systems
      • HPLC Switching Valves
      • FTIR Accessories
  • Service
    • Service and Support Plans
    • Service Request Form
  • Applications
  • KnowledgeBase
  • Learning Center
    • Best Practice
      • Circular Dichroism Tips & Tricks for Biological Samples
      • CD Scale Calibration with ACS
      • Fluorescence Tips & Tricks
      • Raman Spectroscopy Tips & Tricks
    • Training Videos
      • ChromNAV
      • SF-NAV
      • Circular Dichroism
      • UV-Visible/NIR
      • Fluorescence
    • Training Seminars
      • Training Registration Form
    • Webinars
    • eBooks
    • Theory
      • Theory of Molecular Spectroscopy
      • Chromatography
  • About Us
    • President’s Message
    • Contact
    • History
    • Careers
  • News
  • Events
  • Worldwide
  • Shop
  • My Account
  • Contact Us

Home / Applications / Analysis of Aggregates in Antibodies by Size Exclusion Chromatography (SEC)

  • Industry

  • Technique

Analysis of Aggregates in Antibodies by Size Exclusion Chromatography (SEC)

By Heather Haffner

PDF IconDownload This Application

October 9, 2024

Introduction

LC-4000 SeriesIgG, which is a type of antibody, is used as a drug substance for antibody drugs. It is known that IgG may form dimer, trimer, and aggregates due to mechanical stress in each process during manufacturing and environmental factors during transportation and storage. Since aggregates in antibody drugs can reduce drug efficacy and cause side effects, it is necessary to evaluate monomer, multimers, and aggregates for quality control. In 2014, the U.S. Food and Drug Administration (FDA) has provided guidance on the evaluation of immunogenicity of therapeutic protein products and recommended that the validity of each analysis result should be judged while comparing the results using multiple methods (Orthogonal Method) with different measurement principles for protein aggregates contained in biopharmaceuticals. This time, we show the results of measuring human serum-derived IgG reagent by size exclusion chromatography (SEC), which is one of the analytical methods for aggregates, and separating and detecting monomer, multimers, and aggregates.

 

Experimental

PumpPU-4080i
AutosamplerAS-4050i*
Column ovenCO-4060
UV detectorUV-4075*
* with option units
ColumnTSKgel G3000SWXL (7.8 mmI.D. x 300 mmL, 5 µm)
Eluent0.2 mol/L sodium phosphate buffer (pH 6.7)
Flow rate0.8 mL/min
Column temp25 ºC
Wavelength220 nm
Injection volume10 µL
StandardProtein standard mix 15-600 kDa (Merck)
30 mg/mL in water
SampleIgG from human serum (Merck)
1 mg/mL in water

Keywords

747022G, Antibody, IgG, Antibody Drug, Biopharmaceutical, Aggregate, TSKgel G3000SWXL, SEC, UV Detector

Results

Figure 1 shows a UV chromatogram of a protein standard sample. As reference data, an RI chromatogram is also shown, which was measured by connecting an RI detector (RI-4030) downstream of the UV detector.

Fig. 1 Chromatograms of protein standard sample (A) : UV chromatogram, (B) : RI chromatogram 1: Thyrogrobulin (MW 670,000), 2: γ-globulins (MW 150,000), 3: Ovalbumin (MW 44,300), 4: Ribonuclease A (MW 13,700), 5: p-aminobenzoic acid (MW 137)

 

Figure 2 shows a UV chromatogram of human serum-derived IgG reagent. The molecular weight calibration curve is overwritten on this figure. In addition, Table 1 shows the calculation results of the peak-top average molecular weights (Mp) of human serum-derived IgG and the area ratio of each section, and Figure 3 shows the molecular weight distribution curves of each section. From the Mp in Figure 3 and Table 1, it was estimated that peak 4, peak 3, and peaks 2 and 1 correspond to an IgG monomer, dimer, and aggregates with a higher molecular weight, respectively. In addition, based on the ratio of each section area, the human serum-derived IgG reagent measured in this experiment was found to contain approximately 79% of monomer (peak 4) and approximately 21% of aggregates including multimers (peaks 1 to 3).


Fig. 2 UV chromatogram of human serum-derived IgG reagent

 

Peak No.Section Range (min)Baseline Range (min)tR (min)MpSection AreaArea %
15.967-7.3775.967-14.5237.1278350152557202.44
27.377-8.3005.967-14.5238.0175489394265214.07
38.300-9.3735.967-14.5238.810362067149515714.28
49.373-14.1275.967-14.52310.227154964829253879.2
Fig. 3 Molecular weight distribution curves for each section of human serum-derived IgG reagent
(A) : Peak 4, (B) : Peak 3, (C) : Peak 2, (D) : Peak 1

References

U.S. Food and Drug Administration, “Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products.”, https://www.fda.gov/media/85017/download, (2014).

This document has been prepared based on information available at the time of publication and is subject to revision without notice. Although the contents are checked with the utmost care, we do not guarantee their accuracy or completeness. JASCO Corporation assumes no responsibility or liability for any loss or damage incurred as a result of the use of any information contained in this document. Copyright and other intellectual property rights in this document remain the property of JASCO Corporation. Please do not attempt to copy, modify, redistribute, or sell etc. in whole or in part without prior written permission.

About the Author

JASCO Application Note

Analysis of Aggregates in Antibodies by Size Exclusion Chromatography (SEC)

Introduction

LC-4000 SeriesIgG, which is a type of antibody, is used as a drug substance for antibody drugs. It is known that IgG may form dimer, trimer, and aggregates due to mechanical stress in each process during manufacturing and environmental factors during transportation and storage. Since aggregates in antibody drugs can reduce drug efficacy and cause side effects, it is necessary to evaluate monomer, multimers, and aggregates for quality control. In 2014, the U.S. Food and Drug Administration (FDA) has provided guidance on the evaluation of immunogenicity of therapeutic protein products and recommended that the validity of each analysis result should be judged while comparing the results using multiple methods (Orthogonal Method) with different measurement principles for protein aggregates contained in biopharmaceuticals. This time, we show the results of measuring human serum-derived IgG reagent by size exclusion chromatography (SEC), which is one of the analytical methods for aggregates, and separating and detecting monomer, multimers, and aggregates.

 

Experimental

PumpPU-4080i
AutosamplerAS-4050i*
Column ovenCO-4060
UV detectorUV-4075*
* with option units
ColumnTSKgel G3000SWXL (7.8 mmI.D. x 300 mmL, 5 µm)
Eluent0.2 mol/L sodium phosphate buffer (pH 6.7)
Flow rate0.8 mL/min
Column temp25 ºC
Wavelength220 nm
Injection volume10 µL
StandardProtein standard mix 15-600 kDa (Merck)
30 mg/mL in water
SampleIgG from human serum (Merck)
1 mg/mL in water

Results

Figure 1 shows a UV chromatogram of a protein standard sample. As reference data, an RI chromatogram is also shown, which was measured by connecting an RI detector (RI-4030) downstream of the UV detector.

Fig. 1 Chromatograms of protein standard sample (A) : UV chromatogram, (B) : RI chromatogram 1: Thyrogrobulin (MW 670,000), 2: γ-globulins (MW 150,000), 3: Ovalbumin (MW 44,300), 4: Ribonuclease A (MW 13,700), 5: p-aminobenzoic acid (MW 137)

 

Figure 2 shows a UV chromatogram of human serum-derived IgG reagent. The molecular weight calibration curve is overwritten on this figure. In addition, Table 1 shows the calculation results of the peak-top average molecular weights (Mp) of human serum-derived IgG and the area ratio of each section, and Figure 3 shows the molecular weight distribution curves of each section. From the Mp in Figure 3 and Table 1, it was estimated that peak 4, peak 3, and peaks 2 and 1 correspond to an IgG monomer, dimer, and aggregates with a higher molecular weight, respectively. In addition, based on the ratio of each section area, the human serum-derived IgG reagent measured in this experiment was found to contain approximately 79% of monomer (peak 4) and approximately 21% of aggregates including multimers (peaks 1 to 3).


Fig. 2 UV chromatogram of human serum-derived IgG reagent

 

Peak No.Section Range (min)Baseline Range (min)tR (min)MpSection AreaArea %
15.967-7.3775.967-14.5237.1278350152557202.44
27.377-8.3005.967-14.5238.0175489394265214.07
38.300-9.3735.967-14.5238.810362067149515714.28
49.373-14.1275.967-14.52310.227154964829253879.2
Fig. 3 Molecular weight distribution curves for each section of human serum-derived IgG reagent
(A) : Peak 4, (B) : Peak 3, (C) : Peak 2, (D) : Peak 1

Keywords

747022G, Antibody, IgG, Antibody Drug, Biopharmaceutical, Aggregate, TSKgel G3000SWXL, SEC, UV Detector

References

U.S. Food and Drug Administration, “Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products.”, https://www.fda.gov/media/85017/download, (2014).

This document has been prepared based on information available at the time of publication and is subject to revision without notice. Although the contents are checked with the utmost care, we do not guarantee their accuracy or completeness. JASCO Corporation assumes no responsibility or liability for any loss or damage incurred as a result of the use of any information contained in this document. Copyright and other intellectual property rights in this document remain the property of JASCO Corporation. Please do not attempt to copy, modify, redistribute, or sell etc. in whole or in part without prior written permission.
28600 Mary’s Court, Easton, MD 21601 USA • (800) 333-5272 • Fax: (410) 822-7526 • jascoinc.com/applications

Close

Designed in Tokyo. TRUSTED globally.

View our support plans

Connect with JASCO

  • Facebook
  • Twitter
  • LinkedIn
  • JASCO Sales
  • 800-333-5272

Receive the latest promotions and special offers

  • This field is for validation purposes and should be left unchanged.
  • Careers
  • Press Kit
  • JASCO Privacy Policy
  • Sitemap
  • Environmental Policy

© , JASCO. All Rights Reserved.